Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of 4- vs. 3-standard Doses HBV Vaccination in HIV-infected Adults With Isolated Anti-HBc Antibody

NCT03212911 is registered in ClinicalTrials.gov with Chiang Mai University as lead sponsor.

NCT NCT03212911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of 4- vs. 3-standard Doses HBV Vaccination in HIV-infected Adults With Isolated Anti-HBc Antibody
Lead sponsor
Chiang Mai University
Phase
Phase 4
Overall status
Unknown status
Start date
July 1, 2017
Completion date
July 1, 2018
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b vaccination, hiv